Ritchie Bros. Auctioneers (NYSE:RBA) and Protagenic Therapeutics (OTCMKTS:PTIX) are both business services companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.
This table compares Ritchie Bros. Auctioneers and Protagenic Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ritchie Bros. Auctioneers||12.36%||14.15%||5.25%|
Valuation & Earnings
This table compares Ritchie Bros. Auctioneers and Protagenic Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ritchie Bros. Auctioneers||$610.52 million||6.19||$75.02 million||$0.81||42.96|
|Protagenic Therapeutics||N/A||N/A||-$2.25 million||N/A||N/A|
Ritchie Bros. Auctioneers has higher revenue and earnings than Protagenic Therapeutics.
Ritchie Bros. Auctioneers pays an annual dividend of $0.72 per share and has a dividend yield of 2.1%. Protagenic Therapeutics does not pay a dividend. Ritchie Bros. Auctioneers pays out 88.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Ritchie Bros. Auctioneers has raised its dividend for 16 consecutive years.
This is a summary of recent ratings and recommmendations for Ritchie Bros. Auctioneers and Protagenic Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ritchie Bros. Auctioneers||2||8||1||0||1.91|
Ritchie Bros. Auctioneers presently has a consensus target price of $35.38, suggesting a potential upside of 1.65%.
Volatility and Risk
Ritchie Bros. Auctioneers has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of -9.36, meaning that its share price is 1,036% less volatile than the S&P 500.
Insider & Institutional Ownership
91.1% of Ritchie Bros. Auctioneers shares are owned by institutional investors. 1.3% of Ritchie Bros. Auctioneers shares are owned by company insiders. Comparatively, 51.1% of Protagenic Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Ritchie Bros. Auctioneers beats Protagenic Therapeutics on 10 of the 12 factors compared between the two stocks.
Ritchie Bros. Auctioneers Company Profile
Ritchie Bros. Auctioneers Incorporated, an asset management and disposition company, sells industrial equipment and other durable assets through its unreserved auctions, online marketplaces, listing services, and private brokerage services. The company sells a range of used and unused equipment, including earthmoving equipment, truck trailers, government surplus, oil and gas equipment, and other industrial assets. It also provides auction technology services for online bidding at live on site auctions. The company primarily sells equipment to its customers through unreserved auctions at 45 auction sites worldwide. Ritchie Bros. Auctioneers Incorporated was founded in 1958 and is headquartered in Burnaby, Canada.
Protagenic Therapeutics Company Profile
Protagenic Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.
Receive News & Ratings for Ritchie Bros. Auctioneers Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritchie Bros. Auctioneers and related companies with MarketBeat.com's FREE daily email newsletter.